Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Terminated 3Completed 2Unknown 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 49Lymphoid 49Other hematologic neoplasm 32Myeloid 6Genitourinary 5Gastrointestinal 4Dermatologic 4Thoracic 3Gynecologic 3CNS 2Tumor-Agnostic 1Sarcoma 1Classical hematology 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Recurrence 1

Interventions

Carboplatin 158Pemetrexed 135Cisplatin 115pembrolizumab 98Docetaxel 94Paclitaxel 89Gemcitabine 63Erlotinib Hydrochloride 60Radiotherapy 55Nivolumab 55Bevacizumab 46Etoposide 42atezolizumab 33Radiosurgery 33durvalumab 27Cyclophosphamide 22Vinorelbine 21Ipilimumab 21Radiation 20Taxes 17130-nm albumin-bound paclitaxel 17Albumin-Bound Paclitaxel 16Gefitinib 14Irinotecan 13Drug Therapy 13osimertinib 12avelumab 12Magnetic Resonance Spectroscopy 12Dexamethasone 12Vorinostat 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Lenalidomide × Thoracic × Clear all
NCT02963610 2021-12-30

Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer

Fox Chase Cancer Center

Phase 1/2 Terminated
3 enrolled 5 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Recurrence

NCT02018523 2018-01-18

Lenalidomide Maintenance Therapy in Stage IIIB/IV Non-small Cell Lung Cancer

Baylor College of Medicine

Phase 1 Terminated
7 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00179699 2005-11-07

Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung Cancer

Celgene

Phase 1 Terminated
40 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡